Verrica Pharmaceuticals Inc VRCA.OQ VRCA.O is expected to show a fall in quarterly revenue when it reports results on August 12 for the period ending June 30 2025
The West Chester Pennsylvania-based company is expected to report a 17.6% decrease in revenue to $4.267 million from $5.18 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Verrica Pharmaceuticals Inc is for a loss of 70 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Verrica Pharmaceuticals Inc is $40.00, about 84.7% above its last closing price of $6.11
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -1.05 | -0.97 | -1.00 | Missed | -2.6 |
Dec. 31 2025 | -2.84 | -2.62 | -2.40 | Beat | 8.6 |
Sep. 30 2024 | -3.93 | -3.67 | -4.90 | Missed | -33.5 |
Jun. 30 2024 | -4.28 | -4.25 | -3.70 | Beat | 12.9 |
Mar. 31 2024 | -4.58 | -3.97 | -4.40 | Missed | -10.9 |
Dec. 31 2023 | -5.31 | -5.28 | -5.30 | Missed | -0.4 |
Sep. 30 2023 | -3.55 | -3.61 | -5.40 | Missed | -49.5 |
Jun. 30 2023 | -2.21 | -2.10 | -2.40 | Missed | -14.2 |
This summary was machine generated August 8 at 15:22 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)